4.37
+0.1(+2.34%)
Currency In USD
| Previous Close | 4.27 |
| Open | 4.26 |
| Day High | 4.39 |
| Day Low | 4.2 |
| 52-Week High | 12.61 |
| 52-Week Low | 3.72 |
| Volume | 1.13M |
| Average Volume | 1.42M |
| Market Cap | 497.52M |
| PE | -2.25 |
| EPS | -1.94 |
| Moving Average 50 Days | 6.74 |
| Moving Average 200 Days | 8.92 |
| Change | 0.1 |
If you invested $1000 in Cogent Biosciences, Inc. (COGT) since IPO date, it would be worth $98.33 as of April 19, 2025 at a share price of $4.37. Whereas If you bought $1000 worth of Cogent Biosciences, Inc. (COGT) shares 5 years ago, it would be worth $2,801.28 as of April 19, 2025 at a share price of $4.37.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting
GlobeNewswire Inc.
Mar 25, 2025 8:31 PM GMT
Four abstracts accepted for poster presentation highlight Cogent’s expertise in pioneering best-in-class therapeuticsWALTHAM, Mass. and BOULDER, Colo., March 25, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology comp
Cogent Biosciences Announces Participation in the Leerink Healthcare Conference
GlobeNewswire Inc.
Mar 07, 2025 1:00 PM GMT
WALTHAM, Mass. and BOULDER, Colo., March 07, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
GlobeNewswire Inc.
Feb 27, 2025 1:00 PM GMT
65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo
Data not available